SCHEDULE: Paradigm BioCapital Files 13G Amendment for Maze Therapeutics

Paradigm BioCapital entities and Senai Asefaw have filed an amendment to their Schedule 13G, reporting no change in beneficial ownership of Maze Therapeutics common stock as of June 30, 2026.

Summary

• This filing is an amendment to a Schedule 13G for Maze Therapeutics, Inc.
• The reporting persons include Paradigm BioCapital Advisors LP, Paradigm BioCapital Advisors GP LLC, Senai Asefaw, M.D., and Paradigm BioCapital International Fund Ltd.
• As of June 30, 2026, the reporting persons collectively beneficially owned 0.00 shares of Maze Therapeutics' common stock.
• This represents 0.0% of the class of securities.
• The filing indicates no change in beneficial ownership from previous filings.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this as a neutral filing, primarily an amendment to a previous filing with no new material information regarding ownership changes or company performance.

Negatives

• The reporting persons collectively beneficially owned 0.00 shares of Maze Therapeutics' common stock as of June 30, 2026.

Future Outlook

No forward-looking statements or guidance are provided in this filing.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are typically made by institutional investors and significant shareholders to report their ownership stakes. An amendment, especially one reporting zero ownership, suggests a change in the reporting entity's investment strategy or a divestment from the company.

Key Dates

Keywords

Schedule 13G, Amendment, Beneficial Ownership, Paradigm BioCapital, Maze Therapeutics